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Abstract
Aims
Statin-related myopathy (SRM), which includes rhabdomyolysis, is an uncommon but
important adverse drug reaction because the number of people prescribed statins world-
wide is large. Previous association studies of common genetic variants have had limited
success in identifying a genetic basis for this adverse drug reaction. We conducted a multi-
site whole-exome sequencing study to investigate whether rare coding variants confer an
increased risk of SRM.
Methods and results
SRM 3–5 cases (N = 505) and statin treatment-tolerant controls (N = 2047) were recruited
from multiple sites in North America and Europe. SRM 3–5 was defined as symptoms con-
sistent with muscle injury and an elevated creatine phosphokinase level >4 times upper limit
of normal without another likely cause of muscle injury. Whole-exome sequencing and vari-
ant calling was coordinated from two analysis centres, and results of single-variant and
gene-based burden tests were meta-analysed. No genome-wide significant associations
were identified. Given the large number of cases, we had 80% power to identify a variant
with minor allele frequency of 0.01 that increases the risk of SRM 6-fold at genome-wide
significance.
Conclusions
In this large whole-exome sequencing study of severe statin-related muscle injury con-
ducted to date, we did not find evidence that rare coding variants are responsible for this
adverse drug reaction. Larger sample sizes would be required to identify rare variants with
small effects, but it is unclear whether such findings would be clinically actionable.
Introduction
Lipid-lowering drugs that inhibit 5-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA),
known as statins, are widely used for the primary and secondary prevention of cardiovascular
disease (CVD). All statins can cause muscle toxicity that ranges in severity from mild muscle
pain to severe myopathy or rhabdomyolysis, which can lead to kidney failure and death [1].
The most severe forms of statin-related muscle injury are uncommon, suggesting a genetic
predisposition. For instance, severe statin-related myopathy (SRM) restricted to cases with cre-
atine phosphokinase (CK) levels >10x the upper limit of normal (ULN) (SRM 4) requiring
hospitalisation, occurs in approximately 1–10 out of every 10,000 individuals taking standard
statin doses [2].
Previous genome-wide association studies (GWAS) have identified a common variant in
the drug transporter gene SLCO1B1 that increases the risk of SRM defined by varying CK ele-
vation criteria, 2- to 4-fold through a pharmacokinetic mechanism, but the underlying causes
of this adverse drug reaction remain largely unexplained [3–5]. To investigate whether rare
variants in coding regions of the genome may cause SRM, we conducted whole-exome
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Materials and methods
Study population and overall study design
Identification and recruitment of case and control subjects, whole-exome sequencing, variant
calling, and statistical analyses were coordinated by two analysis centers: one based at the Uni-
versity of Washington that included 291 cases and 1540 controls from North America and the
United Kingdom (“US-UK”) and one based in Liverpool that included 214 cases and 507 con-
trols from Europe (“PREDICTION-ADR”). Within each of these two large case-control stud-
ies, participants were recruited from multiple sites. Because there were few non-European
ancestry participants in either case-control study, and many sites had none, we restricted anal-
yses to participants of European ancestry. The details of recruitment at each site are described
in the Supporting Information files. Whole-exome sequencing and variant calling were har-
monized within each of the two case-control studies, and investigators from both studies
agreed prospectively to implement a coordinated statistical analysis plan, which included pro-
tocols for meta-analysis of results from both single-variant and gene-based burden tests. The
University of Washington Human Subjects Division, East of Scotland Research Ethics Service
REC1 and REC2, North West–Liverpool Central Research Ethics Committee, Regional Ethical
Review Boards in Uppsala (2008/213 and 2010/231) and Stockholm (2007/644-31 and 2011/
463-32) and the Medical Ethics Committee from the University Medical Center in Utrecht
reviewed and approved this study.
Case definition
Using a previously published case definition (S1 Table), SRM 3–5 cases received statin treat-
ment at the time of onset of muscle injury symptoms, had a peak CK level> 4x ULN (SRM 3)
or supporting clinical evidence of rhabdomyolysis (SRM 5), and had no other likely cause of
muscle injury other than statin treatment.[1] In each study, non-statin causes of muscle injury
were excluded based on a review of medical records and/or interview of patients by physicians
or study staff. Severe SRM cases (SRM 4) sometimes called severe myopathy and SRM 5, some-
times called rhabdomyolysis in some previous studies [6], met these criteria and had a peak
CK level > 10x ULN (S1 Table). SRM cases with myopathy and evidence of anti-3-hydroxy-
3-methyl-glutaryl-coenzyme A reductase (HMGCR) autoantibodies (SRM 6), which are sug-
gestive of autoimmune myopathy, were excluded at all sites [7]. In both case-control studies,
statin treatment-tolerant controls subjects were users of statins who had no evidence of muscle
injury during follow up.
Whole-exome sequencing, variant calling, quality control
Exome sequencing, variant calling, and quality control of sequence data were performed sepa-
rately in each case-control study (S1 Appendix and S2 Table). Each study conducted sequenc-
ing and called variants for cases and controls together, to eliminate batch effects across case-
control sampling. We created a combined variant annotation file including all quality-con-
trolled variant sites observed in either study. Variants were annotated using ANNOVAR [8]
and dbNSFP v3.0 [9] according to the reference genome GRCh37.
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Statistical analysis
Within each case-control study, which included only European ancestry participants, popula-
tion structure was adjusted for using principal components derived from a genetic relationship
matrix. To estimate associations between single variants and the risk of SRM, the Firth bias-
corrected score test was used [10]. The primary single-variant analysis included all SRM cases
and all control subjects. Single variant analyses were restricted to variants with at least 10 cop-
ies of the minor allele, but not further restricted by annotated variant function. Results from
the two case-control studies were combined using a Z-based meta-analysis [11]. The following
secondary analyses were also conducted: restriction to users of simvastatin, atorvastatin, and
cerivastatin (the three most commonly-used statins in these studies); stratification of SRM
cases into moderate (SRM 3: CK� 4x ULN and<10x ULN) and severe (SRM 4 and 5:
CK� 10x ULN) categories; and inclusion of all missense variants. In the US-UK case-control
study, information on fibrate use was collected. Because fibrates can cause drug-drug interac-
tions with statins through inhibition of the metabolism of statins, and because strong drug-
drug interactions can mask the presence of a genuine drug-gene interaction that may be less
potent, we conducted secondary analyses restricted to non-users of fibrates.
Rare variants (MAF < 1%) were collapsed into gene-burden scores and tested for associa-
tion with the risk of SRM [12]. Gene-burden results from the two case-control studies were
combined using a Z-based meta-analysis. The primary gene-based analysis included variants
with MAF < 1% that are missense, bioinformatically predicted to be damaging (MetaLR > .5)
[13], stop-gain/loss, coding indels, or splice site variants. Secondary gene-burden analyses
restricted to users of simvastatin or atorvastatin, stratified SRM cases into moderate (SRM 3:
CK> = 4x ULN and<10x ULN) and severe (SRM 4 and 5: CK> = 10x ULN) categories, and
included rare missense variants regardless of their prediction score for function.
For each analysis, the Bonferroni-corrected threshold for statistical significance was
P = 0.05 / number of single variants or genes tested. For the primary single-variant analysis, we
conducted post-hoc power calculations using QUANTO 1.1 [14, 15] to determine study power
in the primary analysis population across a range of effect sizes and MAFs, based on α = 0.05 /
number of single variants included in the primary analysis and an estimated disease probabil-
ity among control subjects of 0.0001 [16].
The full results from each meta-analysis will be available on dbGaP within the next release
of Cohort for Heart and Aging Research in Genomic Epidemiology Results CHARGE Consor-
tium summary results (accession phs000930) (http://www.chargeconsortium.com/main/
results). Information on how to access individual-level study data is provided in the Support-
ing Information files.
Results
Across the two case-control studies, there were 505 SRM cases and 2,047 treatment-tolerant
controls that passed sample-level quality control (Table 1). Most of the US-UK cases (mean
CK 159x ULN) were severe (65%) and used cerivastatin or simvastatin, while most of the PRE-
DICTION-ADR cases (mean CK 32x ULN) were moderate (61%) and used simvastatin or
atorvastatin.
Single-variant results
The mean sequencing depth in US-UK case-control study was 78x, and in PREDICTIO-
N-ADR it was 56x. After restricting to rare (MAF < 0.01) likely damaging variants, 162,813
variants passed quality control in one or both studies and were included in meta-analyses (Fig
1). In primary analyses that included all SRM cases and all statin-tolerant controls, there were
Pharmacogenomics of statin-related myopathy
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no variants that met the Bonferroni-corrected threshold for statistical significance (P < 3.07 x
10−7) (Table 2). The widely replicated locus for statin-related muscle injury in SLCO1B1
(rs4149056) was associated with a 1.59-fold increased risk of SRM (95% confidence interval,
1.41–1.77), but this finding was not significant after correction for the number of single vari-
ants tested.
Secondary analyses restricted by statin type and stratified by moderate or severe cases of
SRM did not yield any associations that met criteria for statistical significance (S3 Table).
Among non-users of fibrates in the US-UK case-control study, the SLCO1B1 variant
rs4149056 was associated with a 4.01-fold increased risk of SRM (95% confidence interval,
2.61–6.17), and this association met criteria for statistical significance (P = 5.46 x 10−11) (S4
Table).
Gene-burden results
In total, 10,244 genes passed quality control thresholds in one or both studies and were
included in the meta-analyses of burden test results. In primary analyses of all SRM cases and
all controls, no genes met the Bonferroni-corrected threshold for statistical significance
(P< 4.9 x 10−6) (Table 3). Similarly, none of the secondary burden tests analyses yielded
genome-wide significant findings (S5 Table).
Post-hoc power calculations
We conducted post-hoc power calculations to estimate study power in the primary analysis
population to identify single-variants associated with SRM given a range of MAFs and effect
sizes (Fig 2). For a variant with a MAF of 0.01, we had 98% power to detect an OR of 5, and for
a variant with a MAF of 0.005, we had 84% power to detect an OR of 6.
Table 1. Characteristics of statin-related myopathy cases and statin-tolerant controls from two international case-control studies.
US-UK Cases
N = 291
US-UK Controls
N = 1540
PREDICTION-ADR Cases
N = 214
PREDICTION-ADR Controls
N = 507
Demographic data
Mean age, years (SD) 65 (10.4) 62 (8.3) 66 (11) 69 (9.5)
Age range, years [34, 91] [44, 87] [21, 92] [39, 93]
Gender, % female 44.0% 53.8% 34.1% 36.5%
Statin Type, %
Atorvastatin 32 (11%) 121 (8%) 57 (27%) 129 (25%)
Cerivastatin 146 (50%) 10 (1%) 1 (0%) 0
Fluvastatin 3 (1%) 1 (0%) 4 (2%) 4 (1%)
Pravastatin 7 (2%) 172 13 (6%) 26 (5%)
Rosuvastatin 8 (3%) 130 (12%) 12 (6%) 7 (1%)
Simvastatin 93 (33%) 82 (53%) 127 (59%) 341 (67%)
Lovastatin 0 28 (2%) 0 0
Unknown type 2 (1%) 996 (65%) 0 0
CK/ULN, mean (SD) 159 (325) N/A 32 (74) N/A
CK/ULN, range [4, 529] N/A [4, 542] N/A
Myopathy type
Moderate (SRM 3) 101 (35%) N/A 132 (61%) N/A
Severe (SRM 4 or 5) 190 (65%) N/A 82 (39%) N/A
Severe, no fibrates 98 (34%) N/A 53 (25%) N/A
https://doi.org/10.1371/journal.pone.0218115.t001
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Discussion
We recruited more than 500 patients with statin-related muscle injury from multiple sites in
North America and Europe to conduct the largest whole-exome sequencing study of this
adverse drug reaction to date. Using high-throughput sequencing technology, joint variant
calling at two experienced analysis centres, and rigorous statistical methods, we did not iden-
tify any novel coding variants associated with SRM 3–5. We also evaluated hypotheses about
the burden of rare coding variants within genes, muscle injury due to specific statin drugs, and
the severity of muscle injury; the findings from these analyses were null as well.
In 2008, Link et al. found that a common nonsynonymous variant in the drug transporter
SLCO1B1 (rs4149056) was associated with a 4-fold increase in the risk of myopathy among
Fig 1. Single variant analysis. Single variants included in primarily analysis by frequency (panel A) and type (panel B).
https://doi.org/10.1371/journal.pone.0218115.g001
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users of high dose simvastatin at genome-wide levels of statistical significance [4]. This finding
has been widely replicated in other settings for other statin drugs [3, 5, 17–19], and in our
study this common coding variant was associated with a 4-fold increased risk of SRM 5 among
non-users of fibrates. Interestingly, we did not find an association between the SLCO1B1 poly-
morphisms and mild forms of SRM. Attempts to discover additional common variants related
to statin-related muscle injury have failed to yield replicable findings [20–22]. A recent study
from the Czech Republic conducted whole-exome sequencing on 88 patients with mild statin-
associated muscle toxicity, reporting an increased burden of rare variation in 24 genes [23].
We did not replicate these findings in our study, perhaps due to different phenotypes as most
of our patients have more severe SRM. The validity of these findings may be limited because of
the use of publicly available sequencing repositories that do not have information on medica-
tion use as the referent group rather than statin-tolerant control subjects.
Strengths of our study include the recruitment of patients from multiple international sites;
the use of a standardized case-definition for different forms of myopathy in our study (SRM
3–5) with the mildest being CK>4x ULN (SRM 3) and rhabdomyolysis ranging from CK>10
to>40xULN with end-organ impairment and muscle symptoms[1], the depth of whole-
Table 2. Top associations from meta-analysis of primary single-variant results from US-UK and PREDICTION-ADR case-control studies of statin-related
myopathy.
Ch:position Coded/referent allele MAF P value US-UK
Beta (SE)
PREDICTION
Beta (SE)
Annotation
6:44221262 G/A 0.6% 4.59E-07 2.89 (0.60) NA Nonsynonymous:HSP90AB1
22:20117046 C/T 4.3% 1.04E-06 1.00 (0.24) 0.66 (0.24) Intergenic
12:21331549 C/T 17.8% 1.26E-06 0.59 (0.12) 0.25 (0.15) Nonsynonymous:SLCO1B1
17:4337283 A/G 16.8% 1.84E-06 -0.68 (0.15) NA Synonymous:SPNS3
6:30918065 C/T 0.6% 5.35E-06 2.23 (0.48) NA Synonymous:DPCR1
6:42236725 GCT/G 0.3% 6.95E-06 3.08 (0.74) NA Frameshift:TRERF1
7:21778429 C/T 5.5% 1.79E-05 -0.845 (0.26) -0.73 (0.30) Nonsynonymous:DNAH11
7:36552656 A/G 37.9% 2.49E-05 NA -0.55 (0.13) Utr3:AOAH
6:32261014 A/C 1.4% 2.67E-05 1.02 (0.37) 1.44 (0.45) Nonsynonymous:C6orf10
MAF = minor (coded) allele frequency
https://doi.org/10.1371/journal.pone.0218115.t002
Table 3. Top associations from meta-analysis of primary gene burden results from US-UK and PREDICTION-ADR case-control studies of statin-related
myopathy.
Gene cMAF P value US-UK
Beta (SE)
PREDICTION
Beta (SE)
TRERF1 0.5% 0.00017 2.78 (0.63) 0.98 (2.31)
FOXP4 0.8% 0.00066 1.31 (0.39) 1.22 (1.03)
BAAT 1.3% 0.0011 0.72 (0.34) 1.19 (0.47)
EPB41 1.8% 0.0014 0.69 (0.25) 1.15 (0.67)
ESYT3 3.5% 0.0024 0.62 (0.20) 0.46 (0.35)
NR4A3 2.2% 0.0028 0.41 (0.34) 1.12 (0.40)
TMEM239 0.6% 0.0032 1.89 (0.79) 0.98 (0.56)
FAN1 2.8% 0.0035 0.52 (0.22) 1.09 (0.63)
MYBPH 0.9% 0.0035 1.15 (0.38) 0.68 (0.84)
cMAF = cumulative minor allele frequency
https://doi.org/10.1371/journal.pone.0218115.t003
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exome sequencing in both case-control studies; the use of statin exposed controls to minimize
genetic associations with indications for statin therapy, the coordinated statistical analysis plan
with correction for multiple testing to reduce the risk of false positive findings; and the pro-
spective plan for a meta-analysis of results across two large-case control studies.
There were several limitations. As with any adverse drug reaction, it is difficult to attribute
causality to a specific drug, even with prospectively developed case definitions and expert adju-
dication of cases. In addition, the presence of unknown drug-drug interactions with statin that
increase the risk of SRM may have masked our ability to identify genuine drug-gene interac-
tions. We recognize that our inability to recruit a large number of cases from diverse ancestries
limits the generalizability of our findings to variants observed in European ancestry partici-
pants. Half of the SRM cases in the US-UK case-control study were due to the drug cerivasta-
tin, and we were unable to identify a large number of controls subjects with WES who used
this drug, since it was removed from the market in 2001. If there is heterogeneity in the effects
of genetic variants on the risk of SRM by the type of statin drug or severity of SRM, this might
have reduced our overall power to identify genetic loci for this adverse drug reaction in our
Fig 2. Power calculation. Post-hoc power calculations to identify a single variant associated with statin-related myopathy in primary
analysis population given effect size (odds ratio) and minor allele frequency (MAF), α = 0.05 / 162,813.
https://doi.org/10.1371/journal.pone.0218115.g002
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primary analysis, which included all samples. Finally, using our stringent correction for multi-
ple comparisons, we may have missed an association with rare, loss of function variants in bio-
logically plausible metabolising enzyme or transporter genes that could have led to large
increase in drug exposure and therefore muscle damage in some individuals [24].
While our post-hoc calculations demonstrated that our study was well-powered to identify
rare coding variants (MAF 1%) with large effect sizes (OR 5), we had limited power to detect
rare variants with small- or moderate-sized effects, or to detect even rarer variants with large
effects. For instance, to have 90% power to identify a coding variant with a frequency of 0.001
among controls that increases the risk of SRM 6-fold, we would have to recruit and conduct
whole-exome sequencing on approximately 2,700 cases with this rare adverse drug reaction,
matched with 10,800 treatment-tolerant controls.
It is possible that rare variants exist that increase the risk of SRM, perhaps in non-coding
regions of the genome, but they are unlikely to be detected with the sample sizes available in
ongoing studies. Based on the null findings from our study, genotyping rare coding alleles for
the prediction of severe statin-related muscle injury seems unlikely to yield clinically action-
able findings.
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